Development of a Multi-step Continuous Flow Synthesis of Zidovudine

Yan Chen¹, Rongkun Jiang¹, Fang Zhao^{2*}, and Weiping Zhu^{1,3*}

¹ State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China ² School of Pharmacy, East China Normal University, Shanghai 200241, China ³ Engineering Research Center of Pharmaceutical Process Chemistry, Ministry of Education, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China E-mail: zhao-f06@163.com; wpzhu@ecust.edu.cn



Introduction

The deadliest epidemic of our time is AIDS. Globally, there were approximately 1.3 million new HIV infections and 630,000 AIDS-related deaths in $2023.^{1}$

Thymidine \rightarrow AZT-A \rightarrow AZT-B (%)

Results

Zidovudine is the world's first anti-AIDS drug approved by the US FDA as well as a first-line treatment drug for HIV.





• Poor reaction safety (azidation)

Thymidine

• • •

- Long reaction time
- Low reaction efficiency
- Improved safety

AZT-C

AZT

- Constant reaction
- parameters
- Facile automation





✓ Efficient, flexible, and on-demand production of Zidovudine

Methods

Continuous flow synthesis





Conclusions and Prospects

✓ Under the optimized conditions, the total yield was 69% with a total residence time of 108 min.

✓ Compared with batch process, the new process shortened the reaction time (42.5 h in batch) and improved the safety and efficiency.

Incorporating Process Analytical Technologies into continuous flow processes (e.g., FlowIR, in-line UV-vis, online HPLC...)

□ Automated system

□ Integrated platform



References

[1] The urgency of now: AIDS at a crossroads. Geneva: Joint United Nations Programme on HIV/AIDS; 2024.